关键词： AB, alcian blue AHR, airway hyperresponsiveness AP-1, activator protein 1 Airway BALf, bronchoalveolar lavage fluid BBB, blood–brain barrier COX, cyclooxygenase E-B-NP, encapsulated-Baicalein-nanoparticles ELISA, the enzyme-linked immunosorbent assay FT-IR, fourier-transform infrared spectroscopy Flavonoid H&E, hematoxylin and eosin IL, interleukin IP, intraperitoneal IT, intratracheal Inflammation L-B-NP, loaded-Baicalein-nanoparticles MAP, mitogen-activated protein MCh, methacholine MTT, The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide NF-κB, the nuclear factor-κB Nano OVA, ovalbumin PAS, periodic acid–schiff PG, prostaglandin TNF, tumor necrosis factor Th, T lymphocyte helper iNOS, inducible nitric oxide synthase mV, millivolt nm, nanometer

来  源：   DOI：10.1016/j.sjbs.2021.04.009   PDF(Sci-hub)   PDF(Pubmed)

Abstract：
Asthma as chronic airway disease has high prevalence in children and imbalance of Th1/Th2 is a critical mechanism in pathogenesis of the asthma. Baicalein as a cell protective and anti-inflammatory flavonoid may have anti-asthma effect. Therefore, for better using lung, baicalein was used in chitosan-nanoparticle as anti-asthma treatment. Baicalein was loaded and encapsulated in chitosan nanoparticle. The morphology, physical characters (particle size, zeta potential and FT-IR) were analyzed. Drug encapsulation and loading capacity, accumulative release-time were studied. After asthma model producing, the mice were treated with L-B-NP and E-B-NP. At least, MCh challenge test, Cytokines measurement and Lung Histopathology were done. Nanoparticles had average size 285 ± 25 nm with negative charge -2.5 mV. The L-B-NP decreased penh value and E-B-NP decreased inflammation. Both nanoparticles increased IL-12 and decreased IL-5. Also, L-B-NP decreased mucus secretion in bronchi. L-B-NP and E-B-NP control immune-allergo-inflammatory response of asthma. L-B-NP controlled AHR and E-B-NP controlled inflammation that can be used as controlling anti-asthma drug.
摘要：
哮喘作为慢性气道疾病在儿童中患病率较高，Th1/Th2失衡是哮喘发病的关键机制。黄芩素作为细胞保护和抗炎类黄酮可能具有抗哮喘作用。因此,为了更好地使用肺，黄芩素用于壳聚糖-纳米颗粒的抗哮喘治疗。将黄芩素负载并包封在壳聚糖纳米颗粒中。形态学,物理特征(颗粒大小，zeta电位和FT-IR)进行了分析。药物包封和装载能力，研究了累积释放时间。哮喘模型产生后，用L-B-NP和E-B-NP处理小鼠。至少,MCh挑战测试,进行细胞因子测量和肺组织病理学检查。纳米颗粒的平均尺寸为285±25nm,带负电荷-2.5mV。L-B-NP降低Penh值,E-B-NP降低炎症。两种纳米颗粒均增加IL-12并降低IL-5。此外，L-B-NP减少支气管粘液分泌。L-B-NP和E-B-NP控制哮喘的免疫-变态反应-炎症反应。L-B-NP控制AHR和E-B-NP控制炎症，可用作控制抗哮喘药物。
公众号